Lisa A. Prosser, PhD, MS
Marilyn Fisher Blanch Research Professor of Pediatrics, Medical School
Associate Vice President for Research – Health Sciences, University of Michigan Office of Research
Professor, Department of Health Management and Policy, School of Public Health
Biography
Dr. Prosser is the Marilyn Fisher Blanch Research Professor of Pediatrics. Her research focuses on measuring the value of childhood health interventions using methods of decision sciences and economics. Current research topics include newborn screening programs, vaccination programs, and methods for valuing family spillover effects of illness. She also uses quantitative survey methods (health utility assessment, conjoint analysis) to measure health-related quality of life and preferences for health interventions.
Dr. Prosser’s research evaluating the cost-effectiveness of vaccination programs has been used in setting national vaccine policy for children and adults. Her work with the Evidence Review Group for the Advisory Committee on Heritable Disorders in Newborns and Children using decision science modeling to project long-term health outcomes for proposed newborn screening programs has been used to inform national newborn screening policy decisions. She is currently a member of the evidence review group for the Advisory Committee on Heritable Disorders in Newborns and Children (2007-present), the ACIP Zoster Working Group (2011-present), and the Community Preventive Services Task Force (2024-present).
Dr. Prosser has contributed to faculty development programs at the department, school, and institutional level. She currently serves as the Associate Vice President for Research-Health Sciences. Dr. Prosser also holds an adjunct faculty appointment at the Harvard School of Public Health.
The Valuation of Child Health Initiative (VoCHI) is designed to advance novel research in methods for the economic evaluation of childhood health interventions. Primary areas of research include methods for valuing family spillover effects of illness, equity weighting for cost-effectiveness analysis, approaches for valuing quality of life for childhood conditions, family well-being, and implications of the COVID-19 pandemic on valuation frameworks for health resource allocation. This initiative supports several graduate student research assistant positions.
Education
PhD, Health Policy (Concentration: Decision Sciences), Harvard University, 2000
MS, Technology & Policy, Massachusetts Institute of Technology, 1992
MS, Management, MIT Sloan School of Management, 1992
BA, Mathematics (Concentration: Operations Research), Cornell University, 1988
Projects
Selected Publications
Carlton EF, Weiss SL, Prescott HC, Prosser LA. What’s the Cost? Measuring the Economic Impact of Pediatric Sepsis. Front Pediatr. 2021;9:761994. Published 2021 Nov 15. doi:10.3389/fped.2021.761994
Grosse SD, Kemper AR, Prosser LA. Data Needs for Economic Evaluations of Screening in Pediatric Primary Care: A Research Framework. Pediatrics. 2021;148(Suppl 1):s45-s50. doi:10.1542/peds.2021-050693J
Chen HF, Rose AM, Waisbren S, Ahmad A, Prosser LA. Newborn Screening and Treatment of Phenylketonuria: Projected Health Outcomes and Cost-Effectiveness. Children (Basel). 2021;8(5):381. Published 2021 May 12. doi:10.3390/children8050381
Cernat A, Hayeems RZ, Prosser LA, Ungar WJ. Incorporating Cascade Effects of Genetic Testing in Economic Evaluation: A Scoping Review of Methodological Challenges. Children (Basel). 2021;8(5):346. Published 2021 Apr 27. doi:10.3390/children8050346
Richardson JS, Kemper AR, Grosse SD, Lam WKK, Rose AM, Ahmad A, Gebremariam A, Prosser LA. Health and economic outcomes of newborn screening for infantile-onset Pompe disease. Genet Med. 2021;23(4):758-766. doi:10.1038/s41436-020-01038-0
Hutton DW, McCullough JS, Prosser L, Ye W, Herman WH, Zhang P, Pilishvili T, Pike J. Costs implications of pneumococcal vaccination of adults aged 30-60 with a recent diagnosis of diabetes. Vaccine. 2021;39(8):1333-1338. doi:10.1016/j.vaccine.2020.11.060
Avanceña ALV, Prosser LA. Examining Equity Effects of Health Interventions in Cost-Effectiveness Analysis: A Systematic Review. Value Health. 2021;24(1):136-143. doi:10.1016/j.jval.2020.10.010
Prosser LA. Defining the Value of Treatments of Rare Pediatric Conditions. JAMA Pediatr. 2018;172(12):1123-1124. doi:10.1001/jamapediatrics.2018.3343
Prosser LA, Lam KK, Grosse SD, Casale M, Kemper AR. Using Decision Analysis to Support Newborn Screening Policy Decisions: A Case Study for Pompe Disease. MDM Policy Pract. 2018;3(1):2381468318763814. doi:10.1177/2381468318763814
Sanders GD, Neumann PJ, Basu A, Brock DW, Feeny D, Krahn M, Kuntz KM, Meltzer DO, Owens DK, Prosser LA, Salomon JA, Sculpher MJ, Trikalinos TA, Russell LB, Siegel JE, Ganiats TG. Recommendations for Conduct, Methodological Practices, and Reporting of Cost-effectiveness Analyses: Second Panel on Cost-Effectiveness in Health and Medicine. JAMA. 2016;316(10):1093-1103. doi:10.1001/jama.2016.12195
Wittenberg E, Prosser LA. Health as a Family Affair. N Engl J Med. 2016;374(19):1804-1806. doi:10.1056/NEJMp1604456
Prosser LA, Lamarand K, Gebremariam A, Wittenberg E. Measuring family HRQoL spillover effects using direct health utility assessment. Med Decis Making. 2015;35(1):81-93. doi:10.1177/0272989X14541328
Prosser LA, Harpaz R, Rose AM, Gebremariam A, Guo A, Ortega-Sanchez IR, Zhou F, Dooling K. A Cost-Effectiveness Analysis of Vaccination for Prevention of Herpes Zoster and Related Complications: Input for National Recommendations. Ann Intern Med. 2019;170(6):380-388. doi:10.7326/M18-2347
Research Lab
Our research team evaluates childhood health interventions using methods of decision sciences and economic evaluation. Current projects use cost-effectiveness analysis, simulation modeling to understand the value of interventions projected over the lifespan. We also use quantitative survey methods, including health utility assessment, conjoint analysis, discrete choice experiments, and best-worst scaling to measure values for health and health interventions. Applied topic areas include vaccination, newborn screening, and rare disorders.
Research Team
Acham Gebremariam, MS
Database Analyst / Programmer Senior
Scarlett He
Statistician Intermediate
Angela Rose, MPH, MS
Project Senior Manager
Dhruv Shah
Research Area Specialist Associate